---
title: "AGS invalidated part of the restricted stock for 2023, totaling 81,832 shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/256755521.md"
description: "AGS canceled 81,832 restricted shares in 2023, due to reasons including the departure of incentive targets and failure to meet personal performance assessments. This decision was approved at the Compensation and Assessment Committee meeting of the Board of Directors on August 29, 2025, with the Supervisory Board and lawyers confirming the legality and compliance of the procedures. The company stated that this cancellation will not have a material impact on its financial condition and operating results, nor will it affect the stability of the management team and the implementation of the incentive plan"
datetime: "2025-09-10T12:54:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/256755521.md)
  - [en](https://longbridge.com/en/news/256755521.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/256755521.md)
---

# AGS invalidated part of the restricted stock for 2023, totaling 81,832 shares

On August 29, 2025, AGS held the third meeting of the Compensation and Assessment Committee of the third Board of Directors to review relevant proposals. In September, the fourth meeting of the third Board of Directors and the fourth meeting of the third Supervisory Board passed the proposal to invalidate part of the restricted stock incentive plan for 2023 that had been granted but not yet vested. The reasons for this invalidation include the departure of incentive targets and failure to meet personal performance assessments, totaling 81,832 shares of restricted stock invalidated. The company stated that this invalidation would not have a substantial impact on its financial condition and operating results, nor would it affect the stability of the management team and the implementation of the incentive plan. Both the Supervisory Board and the lawyers believe that the relevant procedures are legal and compliant

### Related Stocks

- [688581.CN](https://longbridge.com/en/quote/688581.CN.md)

## Related News & Research

- [Flow Pharma U.S. Patent Application Allowed for Issuance Covering Broad-Spectrum Ebola Therapy](https://longbridge.com/en/news/287076761.md)
- [Russia plans to return staff to Iranian Bushehr nuclear plant in coming weeks, RIA reports](https://longbridge.com/en/news/286905394.md)
- [Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates](https://longbridge.com/en/news/287103520.md)
- [13:41 ETUT Haslam Marks Decade in Major International Ranking's Top Five U.S. Public Schools](https://longbridge.com/en/news/286804132.md)
- [Allen & Heath Rolls Out New SQ+ Lineup of Digital Mixers Announced; First Look YouTube Video on SQ5+,   SQ6+, and   SQ7+ Digital Mixers at B&H](https://longbridge.com/en/news/287101198.md)